Key market opportunities in Q1 2026 include significant regulatory catalysts like approvals for GSK's depemokimab, Regenxbio's gene therapy, and Omeros' narsoplimab. Ongoing trials by Xenon, Cerevel, ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果